The evidence for Cannabidiol is building
Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by NICE.
Recent Posts
Cancer Productivity Disparities in the Asia-Pacific Region
New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...
Generative AI Diagnosis in Neurology Enhances Non-Specialist Accuracy
Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...
Enhancing Tuberculosis Outcomes Through Counselling Incentives
Tuberculosis counselling incentives that combine conditional cash transfers with structured pre- and post-test counselling are proving highly effective at overcoming socioeconomic barriers to treatment adherence. This integrated strategy reduces long-term disease transmission while requiring only...